Trials that use: Risk ratio / relative risk
New to this method? Read the tutorial →
6,204 results
- Neoadjuvant Pazopanib in Renal Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Neoadjuvant Pazopanib in Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01361113).
- Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2: Complete Statistical AnalysisIndependent statistical analysis of Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2: primary endpoint results, effect estimate…
- Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00828308).
- NeohttpIndependent statistical analysis of Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02345772).
- NeoMatriX Wound Matrix Collagen Dressing Skin Prick Test: Complete Statistical AnalysisIndependent statistical analysis of NeoMatriX Wound Matrix Collagen Dressing Skin Prick Test: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03522675).
- NEOMUNIndependent statistical analysis of Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03197467).
- Neonatal Outcome by Reason for Delivery: Complete Statistical AnalysisIndependent statistical analysis of Neonatal Outcome by Reason for Delivery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01818518).
- NEOTHROCOVIDIndependent statistical analysis of Thromboembolic Risk Screening in Patients With Cancer and COVID-19: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04616846).
- Nerve Ablation by Cooled Radiofrequency Compared to Corticosteroid Injection for Management of Knee Pain: Complete Statistical AnalysisIndependent statistical analysis of Nerve Ablation by Cooled Radiofrequency Compared to Corticosteroid Injection for Management of Knee Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Nerve Stimulator for Patients With Upper Extremity Disease, Vascular or Orthopedic Surgery: Complete Statistical AnalysisIndependent statistical analysis of Nerve Stimulator for Patients With Upper Extremity Disease, Vascular or Orthopedic Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nesiritide Use Following Cardiac Surgery in Infants: Complete Statistical AnalysisIndependent statistical analysis of Nesiritide Use Following Cardiac Surgery in Infants: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00281671).
- NEST-1Independent statistical analysis of Combination Immunotherapy in Colorectal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05571293).
- NeuHFRecoverIndependent statistical analysis of NMES in HF Patients to Improve Functional Recovery Following Hospitalization: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05338437).
- Neuraxial Preservative Free Morphine for Normal Spontaneous Vaginal Delivery: Complete Statistical AnalysisIndependent statistical analysis of Neuraxial Preservative Free Morphine for Normal Spontaneous Vaginal Delivery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04017442).
- Neurodevelopmental Outcomes in Craniosynostosis Repair: Complete Statistical AnalysisIndependent statistical analysis of Neurodevelopmental Outcomes in Craniosynostosis Repair: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04072783).
- Neuroimaging Biomarkers of Prognosis in Motor Functional Neurological Disorders: Complete Statistical AnalysisIndependent statistical analysis of Neuroimaging Biomarkers of Prognosis in Motor Functional Neurological Disorders: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03398070).
- Neuropathic Pain Syndrome Patient Study (MK-0000-072): Complete Statistical AnalysisIndependent statistical analysis of Neuropathic Pain Syndrome Patient Study (MK-0000-072): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00570310).
- Neuroprotective Effects of Lithium in Patients With Small Cell Lung Cancer Undergoing Radiation Therapy to the Brain: Complete Statistical AnalysisIndependent statistical analysis of Neuroprotective Effects of Lithium in Patients With Small Cell Lung Cancer Undergoing Radiation Therapy to the Brain: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- New Onset Type 1 Diabetes: Role of Exenatide: Complete Statistical AnalysisIndependent statistical analysis of New Onset Type 1 Diabetes: Role of Exenatide: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01269034).
- New Treatment for Alcohol and Nicotine Dependence: Complete Statistical AnalysisIndependent statistical analysis of New Treatment for Alcohol and Nicotine Dependence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01182766).
- NewHopeIndependent statistical analysis of Naltrexone for Opioid Dependent Released Human Immunodeficiency Virus Positive (HIV+) Criminal Justice Populations: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- NEwTON AFIndependent statistical analysis of Clinical Evaluation of the StablePoint Catheter and Force Sensing System for Paroxysmal Atrial Fibrillation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- NEXSCOTIndependent statistical analysis of Study of Various Treatments in Non-alcoholic Fatty Liver Disease (NAFLD) Patients Who Have Aspects of Non-alcoholic Steatohepatitis (NASH): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Next Generation X-ray Imaging System: Complete Statistical AnalysisIndependent statistical analysis of Next Generation X-ray Imaging System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04571099).
- NEXT2Independent statistical analysis of Efficacy of Esomeprazole in Patients With Frequent Heartburn: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01370538).
- NF107-BMP2Independent statistical analysis of A Study of INFUSE Bone Graft (BMP-2) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis Type 1 (NF1): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- NFPIndependent statistical analysis of Nurse-Family Partnership Impact Evaluation in South Carolina: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03360539).
- NGAM-05Independent statistical analysis of High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01313507).
- NHLBI DIR LAMPOON Study: Intentional Laceration of the Anterior Mitral Leaflet to Prevent Left Ventricular Outflow Tract Obstruction During Transcatheter Mitral Valve Implantation: Complete Statistical AnalysisIndependent statistical analysis of NHLBI DIR LAMPOON Study: Intentional Laceration of the Anterior Mitral Leaflet to Prevent Left Ventricular Outflow Tract Obstruction During Transcatheter Mitral Valve Implantation: primary endpoint results, effect estimate…
- NHLBI DIR Transcatheter Mitral Cerclage Annuloplasty Early Feasibility Study: Complete Statistical AnalysisIndependent statistical analysis of NHLBI DIR Transcatheter Mitral Cerclage Annuloplasty Early Feasibility Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03929913).
- NIAGARAIndependent statistical analysis of Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nicotine Pharmacokinetics and Pharmacodynamics, Safety and Tolerability of P3P: Complete Statistical AnalysisIndependent statistical analysis of Nicotine Pharmacokinetics and Pharmacodynamics, Safety and Tolerability of P3P: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03369340).
- NIHO12Independent statistical analysis of Accuracy of Pulse Oximeters With Profound Hypoxia During Motion: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04814342).
- NIKAIA 1Independent statistical analysis of To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus: primary endpoint results, effect estimate…
- NILOdeepRIndependent statistical analysis of Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor: Complete Statistical AnalysisIndependent statistical analysis of Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV: Complete Statistical AnalysisIndependent statistical analysis of Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1): Complete Statistical AnalysisIndependent statistical analysis of Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC): Complete Statistical AnalysisIndependent statistical analysis of Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02389764).
- Ninvasive Cardiac Output Measurements During Cesarean Delivery Under Spinal Anesthesia.: Complete Statistical AnalysisIndependent statistical analysis of Ninvasive Cardiac Output Measurements During Cesarean Delivery Under Spinal Anesthesia.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01928797).
- Niraparib + Dostarlimab + RT in Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Niraparib + Dostarlimab + RT in Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04409002).
- Niraparib + Dostarlimab In BRCA Mutated Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Niraparib + Dostarlimab In BRCA Mutated Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04584255).
- Nitrite Infusion in Islet Cell Transplantation: Complete Statistical AnalysisIndependent statistical analysis of Nitrite Infusion in Islet Cell Transplantation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03544242).
- Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03693846).
- Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression: Complete Statistical AnalysisIndependent statistical analysis of Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…